Casdin Partners Master Fund, L.P.

Casdin Partners Master Fund, L.P. has filed trades across 6 companies (mainly through SEC (Form 4)), most often in Standard Biotools Inc., Biolife Solutions Inc and Maxcyte, Inc. In total, 47 filings cover trades dated from 21 June 2021 to 21 May 2026.

In open-market terms, that means 28 purchases worth €47.6M on one side and 9 sales worth €101.5M on the other. The net balance comes to €53.9M on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 2 share grants. Since January 2026: no purchases and 3 sales on the market.

The median purchase comes to €451k. On 1 out of 28 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. For 20 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 30% of cases, with a median move of -10.3%. They describe history only and say nothing certain about the share price ahead.

On 21 May 2026 came the latest disclosure, an open-market sale for €5.1M in Biolife Solutions Inc. The last insider purchase was made public on 4 December 2025, 318 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.